Abstract
Background:
Currently, there are no guidelines or consensus statements about the usage of inhaled mucoactive drugs in pediatric respiratory disease conditions from an Indian perspective.
Objective:
To develop a practical consensus document to help pediatricians in clinical decision-making when choosing an appropriate mucoactive drug for the management of specific respiratory disease conditions.
Methods:
A committee of nine experts with significant experience in pediatric respiratory disease conditions and a microbiological expert constituted the panel. An electronic search of the PubMed/MEDLINE, Cochrane Library, Scopus, and Embase databases was undertaken to identify relevant articles. Various combinations of keywords such as inhaled, nebulized, mucoactive, mucolytic, mucokinetic, expectorants, mucoregulators, mucociliary clearance, respiratory disorders, pediatric, cystic fibrosis (CF), non-CF bronchiectasis, acute wheezing, asthma, primary ciliary dyskinesia (PCD), critically ill, mechanical ventilation, tracheomalacia, tracheobronchomalacia, esophageal atresia (EA), tracheoesophageal fistula (TEF), acute bronchiolitis, sputum induction, guideline, and management were used. Twelve questions were drafted for discussion. A roundtable meeting of experts was conducted to arrive at a consensus. The level of evidence and class of recommendation were weighed and graded.
Conclusions:
Inhaled mucoactive drugs (hypertonic saline, dry powder mannitol, and dornase alfa) can enhance mucociliary clearance in children with CF. Experts opined that hypertonic saline could be beneficial in non-CF bronchiectasis, acute bronchiolitis, and PCD. The current state of evidence is inadequate to support the use of inhaled mucoactive drugs in asthma, acute wheezing, tracheomalacia, tracheobronchomalacia, and EA with TEF.
1. Introduction
India has a high burden of acute and chronic respiratory diseases. Pediatric respiratory diseases place a substantial financial and human resource strain on our healthcare system every year. Several childhood disorders, such as primary ciliary dyskinesia (PCD), cystic fibrosis (CF), non-CF bronchiectasis, and severe asthma exhibit airway mucus hypersecretion (1). Mucoactive drugs have a long and well-established record of being an effective therapy for the management of respiratory diseases in which mucus hypersecretion is a clinical challenge (1, 2). Mucoactive drugs are classified as expectorants, mucoregulators, mucolytics, or mucokinetic drugs based on their potential mechanism of action (Figure 1) (1, 2). Inhaled mucoactive drugs are delivered directly to the airway and are used to improve mucus properties and reduce the mucus load in the lungs of patients suffering from muco obstructive pulmonary illness (1, 2). In this article, we have attempted to review the available literature and summarize recommendations on the role of inhaled mucoactive drugs in pediatric respiratory disease conditions from an Indian perspective.
Figure 1
2. Methodology
2.1. Panel selection
A panel consisting of nine experts (mean age: 53.5 years; specialty: pediatrics) with significant experience in pediatric respiratory disease conditions and a microbiological expert participated in the development of this consensus manuscript (Supplementary Table S1). Panel members were carefully selected based on their wide clinical expertise and knowledge in the field. A minimum of 10 years of clinical expertise in the field was mandatory. A moderator was identified among the panel to drive the consensus process.
2.2. Evidence review
An electronic search of the PubMed/MEDLINE, Cochrane Library, Scopus, and Embase databases was undertaken to identify relevant articles between January 1980 and August 2022. Various combinations of keywords such as “inhaled,” “nebulized,” “mucoactive,” “mucolytic,” “mucokinetic,” “expectorants,” “mucoregulators,” “mucociliary clearance,” “respiratory disorders,” “pediatric,” “cystic fibrosis,” “non-cystic fibrosis bronchiectasis,” “acute wheezing,” “asthma,” “primary ciliary dyskinesia,” “critically ill,” “mechanical ventilation,” “tracheomalacia,” “tracheobronchomalacia,” “esophageal atresia,” “tracheoesophageal fistula,” “acute bronchiolitis,” “sputum induction,” “guideline,” and “management” were used. Appropriate variations in search phrases and Boolean operators (AND, OR) were used. Randomized controlled trials, case reports, practice guidelines, systematic literature reviews, and meta-analyses were included. Animal studies and studies published in a language other than English were excluded. Duplicates were removed during the screening procedure. After an extensive search, 12 clinically relevant questions (Supplementary Table S2) were drafted to facilitate discussion. A virtual meeting was conducted on 24 June 2022 to finalize the questionnaire. Key articles were shortlisted and circulated among the expert panel members.
2.3. Consensus process
The class of recommendation (COR) and certainty of evidence (COE) were weighed and graded according to predefined scales as outlined in Table 1 (3–5). The COR was based on the grading system used by Knuuti et al., which was suitably modified and adapted to current settings (3). A roundtable meeting of experts was held on 23 August 2022 to finalize the recommendations on the role of inhaled mucoactive drugs in pediatric respiratory disease conditions. To assess the COE, we employed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) technique, as defined in the GRADE handbook (4, 5). The COE for each of the outcomes was independently evaluated by two authors. We rated the evidence from RCTs as being of high quality and downgraded it to one level for serious (or two levels for very serious) limitations based on the following considerations: design (risk of bias), consistency across studies, directness of evidence, precision of estimates, and presence of publication bias. After the group discussion, clinical consensus statements were formulated based on the opinions and agreement of the majority. During group discussions, all panelists were encouraged to participate actively. The differences in opinions were discussed and resolved. Certain recommendations are based on the collective clinical judgment from real-world practice and no grading of recommendations has been applied for the same. A draft of the clinical consensus statements and recommendations was circulated among the expert panel for review. After the second meeting, the experts discussed updating any new findings (if any). A second round of basic literature searches was conducted in PubMed/MEDLINE, Cochrane Library, Scopus, and Embase databases in June 2023 to check for any new updates/findings. The final draft of the clinical consensus statements and recommendations was circulated among the expert panel for final review and approval in the first week of July 2023.
Table 1
| 1. Class of recommendation (COR) | ||
| Class I | “Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, or effective” | “Agreement” (“Recommended” or “indicated”) |
| Class II | “Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure” | “Conditional agreement” (“May be considered”) |
| Class III | “Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful” | “Disagreement” (“Not recommended”) |
| 2. Certainty of evidence (COE) | ||
| High | “Further research is very unlikely to change our confidence in the estimate of the effect” | |
| Moderate | “Further research is likely to have an important impact on our confidence in the estimate of the effect and may change the estimate” | |
| Low | “Further research is very likely to have an important impact on our confidence in the estimate of the effect and is likely to change the estimate” | |
| Very low | “Any estimate of effect is very uncertain” | |
Definitions: (A) class of recommendation; and (B) certainty of evidence.
3. Results
3.1. Cystic fibrosis
Cystic fibrosis is a genetic illness caused by a gene defect on chromosome 7 that encodes for CF transmembrane conductance regulator (CFTR) protein (6). In patients with CF, mucociliary clearance is impaired. Evidence (Table 2) showed that inhaled hypertonic saline (HS; an expectorant) enhanced mucociliary clearance (15), improved lung clearance index (8, 16), and reduced pulmonary exacerbations (17) in children with CF as compared with isotonic saline. Salbutamol followed by inhaled 3% HS positively affected structural lung changes relative to 0.9% saline (9). Higher HS strengths (5%, 6%, or 7%) may have the same or better effect. However, more research is needed in a developing country setting like India. In children with CF, the use of inhaled mannitol, a hyperosmotic mucoactive drug, also resulted in an improvement in lung function [forced expiratory volume in 1 s (FEV1)] (12, 18, 19). Clinical evidence supports the use of recombinant human DNAase I (rhDNase; dornase alfa), a mucolytic drug as it improved lung function (FEV1) and reduced pulmonary exacerbations in children with CF (20, 21). N-acetylcysteine (NAC), a mucolytic drug, causes cleavage of disulfide bonds to two sulfhydryl groups, resulting in thinning of the mucus (1). No beneficial effect of NAC on lung function has been reported in children with CF (14). Heparin inhalation showed no significant effect on sputum clearance, FEV1, or sputum inflammatory markers in adults with CF (22). Currently, there is no evidence of the role of inhaled heparin in children with CF.
Table 2
| Author and year | Study design and study groups | Key findings | Quality/certainty of evidence (per GRADE criteria) |
|---|---|---|---|
| HS and NS | |||
| Wark et al. (7) | Systematic review | CF with stable lung disease (246 participants from four trials):
| Very low COE. More data are needed. |
CF with acute exacerbation (130 participants from one trial):
| Very low COE More data are needed. | ||
| Ratjen et al. (8) |
| 150 preschool children (3–6 years of age) with early CF lung disease.
| Low COE More data are needed. |
| Tiddens et al. (9) |
| 116 preschool children (3–6 years of age) with early CF lung disease.
| Low COE More data are needed. |
| HS (3%–7%) vs. rhDNase | |||
| Wark et al. (7) | Systematic review | CF with stable lung disease (61 participants from two trials):
| Very low COE More data are needed. |
| Low COE More data are needed. | |||
| HS (3%–7%) vs. mannitol | |||
| Wark et al. (7) | Systematic review | CF with stable lung disease (12 participants from one trial):
| Very low COE More data are needed. |
| HS 3% vs. 7% | |||
| Wark et al. (7) | Systematic review | CF with stable lung disease (30 participants from one trial):
| Very low COE More data are needed. |
| Timing of HS administration | |||
| Elkins et al. (10) | Systematic review | CF with stable lung disease (77 participants from three trials):
| Low COE More data are needed. |
| Inhaled dry powder mannitol vs. nonrespirable mannitol or rhDNase or HS | |||
| Nevitt et al. (11) | Systematic review | CF with stable lung disease (784 participants from six studies):
| Low to very low COE. More data are needed. Moderate COE Low COE More data are needed. |
| Sadr et al. (12) |
| CF with stable lung disease (30 participants from one trial):
| Very-low COE More data are needed. |
| rhDNase vs. placebo, no treatment, or HS | |||
| Yang et al. (13) | Systematic review | Dornase alfa compared with placebo or no treatment (1,708 participants from eight trials):
| Moderate to high COE |
Daily vs. alternate day (43 participants from one trial):
| Low COE More data are needed. | ||
Compared with HS (43 participants from one trial):
| Low COE More data are needed. | ||
| NAC (inhaled or oral) vs. placebo | |||
| Duijvestijn et al. (14) | Systematic review | Nebulized NAC (28 participants from three trials):
| Very low COE More data are needed. |
Oral NAC (181 participants from six trials):
| Very low COE More data are needed. | ||
Clinical studies of inhaled mucoactive drugs in CF.
ACT, airway clearance technique; AE, adverse event; CF, cystic fibrosis; COE, certainty of evidence; CT, computed tomography; FEF25–75, forced expiratory flow at 25%–75% of FVC; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GRADE, grading of recommendations assessment, development and evaluation; HS, hypertonic saline; LCI, lung clearance index; MD, mean difference; NAC, N-acetylcysteine; NS, normal saline; QoL, quality of life; RCT, randomized controlled trial; rhDNase, recombinant human deoxyribonuclease I.
3.1.1. Expert opinions/consensus recommendations
Children with CF would benefit from initiation of HS inhalation (6% or 7%; twice or thrice daily) from the time of diagnosis (COR: I, agreement, very low CoE).
The experts concurred that HS inhalation (6% or 7%; twice or thrice daily) as an adjunct to the airway clearance technique (ACT) can enhance mucociliary clearance and reduce pulmonary exacerbations in children with CF based on real-world practice (COR: II, conditional recommendation, very low CoE). As local side-effects are common after a higher strength of HS (6% and 7%) that may affect tolerability, more research on 3% HS is needed.
Inhaled dry powder mannitol (400 mg; twice daily) is useful for clearing retained airway secretions in children with CF (COR: II, conditional recommendation, very low to low CoE). However, a mannitol dry powder inhaler is currently unavailable in India for managing mucus hypersecretion in children with CF. The experts suggested that tolerability testing is needed before treatment.
Dornase alfa (rhDNAse; 2.5 mg; once or twice daily) in nebulized form is useful in reducing the risk of exacerbations of respiratory symptoms requiring parenteral antibiotics in children with CF (COR: I, agreement, moderate to high COE). However, rhDNase is currently unavailable in India and the cost associated with therapy is high for managing mucus hypersecretion in children with CF.
The use of NAC is not beneficial in children with CF. However, more data are needed (COR: III, disagreement, very low COE).
3.2. Non-CF bronchiectasis
Bronchiectasis is a chronic respiratory disease associated with wet cough in children and recurrent infective exacerbations impacting the quality of life (QoL) (23, 24). Treatment for non-CF bronchiectasis consists of management of nutrition, airway clearance, and antibiotics for exacerbations (23, 24). Tarrant et al. systematically reviewed the effects of mucoactive drugs in chronic non-CF bronchiectasis. Both HS (6% or 7%) and normal saline (0.9% sodium chloride; NS) improved FEV1, forced vital capacity (FVC), and forced expiratory flow25%–75% (FEF25%–75%) in bronchiectasis after one dose and after 3–12 months (25). Mannitol failed to improve spirometry in bronchiectasis. On the contrary, rhDNase caused significant reductions in FEV1 and FVC, but increased exacerbation rate, and reduced spirometry (25). Another review of inhaled HS in bronchiectasis found that it improved expectoration, reduced sputum viscosity, improved lung function, and reduced the frequency of exacerbations (23). The British Thoracic Society guidelines for the management of non-CF bronchiectasis in adults mention that inhaled HS may be used as an adjunct to physiotherapy (26). The use of rhDNase is not advised as it worsens lung function due to an increase in exacerbation frequency. In addition, it states that there is no definitive clinical evidence to confirm its use in children or adults with bronchiectasis (26). Anuradha et al. highlighted that inhaled salbutamol (200 µg) followed by 3% HS nebulization twice daily for 8 weeks before chest physiotherapy significantly improved FEV1 in children (N = 26; 5–15 years of age) with non-CF bronchiectasis (27). In addition, improvement in FVC and reduction in the frequency of exacerbation were significant compared with conventional ACT (N = 26; inhaled salbutamol before chest physiotherapy) (27). Table 3 lists clinical studies of inhaled mucoactive drugs in chronic non-CF bronchiectasis.
Table 3
| Author and year | Study design | Key findings | Quality/certainty of evidence (per GRADE criteria) |
|---|---|---|---|
| HS vs. NS | |||
| Tarrant et al. (25) | Systematic review | Chronic non-CF bronchiectasis (92 adult participants from three trials):
| Low COE (based on the pooled data from these trials). Data needed in the pediatric population. |
| Mannitol vs. placebo | |||
| Tarrant et al. (25) | Systematic review | Chronic non-CF bronchiectasis [804 pediatric (adolescent) and adult participants from two trials]: | Low COE Data exclusively on the pediatric population are needed. |
| rhDNase vs. placebo | |||
| Tarrant et al. (25) | Systematic review | Chronic non-CF bronchiectasis (409 adult participants from two trials): | Moderate COE Data needed in the pediatric population. |
| NAC | |||
| No trials were identified | |||
Clinical studies of inhaled mucoactive drugs in chronic non-CF bronchiectasis.
AE, adverse event; CF, cystic fibrosis; COE, certainty of evidence; GRADE, grading of recommendations assessment, development and evaluation; HS, hypertonic saline; NS, normal saline; NAC, N-acetylcysteine; QoL, quality of life; rhDNase, recombinant human deoxyribonuclease I.
3.2.1. Expert opinions/consensus recommendations
Evidence on the efficacy and safety of inhaled HS in adults with non-CF bronchiectasis is available, and it is beneficial (low CoE). More research into the pediatric population is required. Based on the data available for adults, the experts proposed that the inhaled HS before chest physiotherapy can be tried in children with non-CF bronchiectasis until more data are available.
The HS inhalation is associated with the risk of bronchospasm. Based on real-world experience similar to that of children with CF, the experts suggested that inhaled salbutamol followed by HS before chest physiotherapy and postural drainage can be helpful in children with non-CF bronchiectasis. Multicenter RCTs are required to evaluate the efficacy and safety of inhaled HS in children with non-CF bronchiectasis.
Evidence on the efficacy and safety of inhaled mannitol in adolescents and adults with non-CF bronchiectasis is available (low CoE). However, inhaled mannitol may not be readily available in India, and data on children are required.
There are no pediatric studies that assessed the efficacy and safety of rhDNase in non-CF bronchiectasis. The data in adults show that it worsens lung function (moderate CoE). Thus, the experts agreed that, currently rhDNase should not be used in children with non-CF bronchiectasis.
3.3. Acute wheezing
Ater et al. studied the effectiveness of 5% HS on acute wheezing (Table 4A) in children after salbutamol inhalation relative to NS (35). Inhaled HS substantially shortened the stay and admission rate (35). In children with acute viral wheeze, HS/salbutamol significantly reduced hospital stay and oxygen therapy time, and improved asthma clinical severity score quicker than NS/salbutamol (36).
Table 4
| Author and year | Study design and study groups | Key findings | Quality/certainty of evidence (per GRADE criteria) |
|---|---|---|---|
| HS vs. NS | |||
| Under-five wheezing Ater et al. (35) |
| Under-five wheezing (acute, moderate to severe wheezing) (41 children):
| Low COE More data are needed. |
| Under-five wheezing Kanjanapradap et al. (36) |
| Under-five wheezing (acute, moderate to severe wheezing) (47 children):
| |
| Asthma Teper et al. (37) |
| Stable asthma (50 children):
| |
Clinical studies of inhaled mucoactive drugs in under-five wheezing (A) and asthma (B).
COE, certainty of evidence; ED, emergency department; FEV1, forced expiratory volume in 1 s; GRADE, grading of recommendations assessment, development and evaluation; GRADE, grading of recommendations assessment, development and evaluation; HS, hypertonic saline; NS, normal saline; RCT, randomized controlled trial.
3.3.1. Expert opinions
HS alone has never been used to treat children with acute wheezing as it can provoke bronchospasm.
HS (5% and 3%), when used along with salbutamol, has been shown in two studies by Ater D et al. (35) and Kanjanapradap T et al. (36) to have a positive effect (shorter length of hospital stay) in preschool wheeze relative to NS. However, the experts unanimously agreed that the current state of evidence is inadequate to recommend the routine use of HS in clinical practice in children with acute wheezing. (COR: III, disagreement, low CoE).
3.4. Asthma
Asthma is an inflammatory chronic airway disease characterized by bronchial hyperresponsiveness and airflow obstruction. Wheezing, mucus hypersecretion, and mucus plugging are reported in patients with asthma, especially during exacerbations (37). Short-acting beta2-agonist bronchodilators, such as salbutamol and systemic corticosteroids, are usually advised for asthma exacerbations (37). It has also been seen that salbutamol produced a greater bronchodilator response (FEV1 and maximum mid-expiratory flow) when inhaled with 3% HS vs. NS in asthmatic children with mild or moderate bronchial obstruction (Table 4B) (37).
3.4.1. Expert opinions/consensus recommendations
HS alone has never been used to treat children with asthma as it can provoke bronchospasm.
The current state of evidence is inadequate to recommend the routine use of HS in clinical practice for asthma. There is a need for well-designed multicenter RCTs to assess the role of HS in children with asthma. (COR: III, disagreement, very low CoE).
3.5. Primary ciliary dyskinesia
Primary ciliary dyskinesia is a rare disorder characterized by motile ciliary dysfunction. This leads to an array of clinical manifestations, including neonatal respiratory distress (in term infants), persistent wet cough, rhinitis without remission, chronic sinusitis (in childhood), and bronchiectasis (in adolescence) (38). Currently, there is a lack of RCTs that have assessed the effectiveness of mucoactive drugs in children with PCD. Few case studies have highlighted the use of inhaled HS and rhDNase in the management of PCD in children (39, 40). The European Respiratory Society (ERS) consensus statement suggests: (i) inhaled NS or HS to increase mucus clearance (low-quality evidence, weak recommendation); or (ii) inhaled rhDNase in selected patients with PCD (low-quality evidence, weak recommendation) (38). Pediatric PCD patients require mucus hypersecretion management when they develop bronchiectasis, also known as non-CF bronchiectasis. Table 5 lists clinical studies of inhaled mucoactive drugs in the management of PCD.
Table 5
| Author and year | Study design and study groups | Key findings | Quality/certainty of evidence (per GRADE criteria) |
|---|---|---|---|
| HS vs. NS | |||
| Paff et al. (41) |
| PCD (44 adult participants):
| Very low COE. More data are required in the pediatric population. |
| HS | |||
| Kaspy et al. (42) | Retrospective study | PCD (34 infants):
| Very low COE. More data are needed on infants and children. |
| NAC vs. placebo | |||
| Stafanger et al. (43) | RCT | PCD (13 participants):
| Very low COE. More data are needed on the pediatric population. |
| Dornase alfa | |||
| No trials were identified | |||
Clinical studies of inhaled mucoactive drugs in PCD.
AE, adverse event; COE, certainty of evidence; GRADE, grading of recommendations assessment, development and evaluation; HS, hypertonic saline; NAC, N-acetylcysteine; NS, normal saline; PCD, primary ciliary dyskinesia; QoL, quality of life; RCT, randomized controlled trial.
3.5.1. Expert opinions/consensus recommendations
There is a lack of RCTs that have assessed the effectiveness of inhaled HS in children with PCD. Adult studies of inhaled HS or NS on non-CF bronchiectasis show beneficial effects. Thus, the evidence on adults can be extrapolated to pediatrics. In line with the ERS consensus statement, the experts agreed that the use of inhaled NS or HS should possibly be considered to increase mucus clearance in patients with PCD (COR: II, conditional agreement) (38).
The use of NAC is not recommended in children with PCD (COR: III, disagreement, very low CoE).
3.6. Critically Ill on mechanical ventilator support
Ventilator-associated pneumonia (VAP) is a serious complication related to mechanical ventilation in the neonatal period in pediatric intensive care units. Ezzeldin et al. found a significant reduction in the incidence density of VAP (Table 6) with a 3% HS group as an adjunct to VAP prevention protocol in intubated and mechanically ventilated premature infants (46).. In mechanically ventilated children after cardiac surgery, inhaled rhDNase resulted in a reduction in the duration of ventilator support by approximately 1 day and lowered the incidence of atelectasis vs. NS (47).
Table 6
| Author and year | Study design and study groups | Key findings | Quality/certainty of evidence (per GRADE criteria) |
|---|---|---|---|
| Mucoactive agents | |||
| Anand et al. (44) | Systematic review | Patients on mechanical ventilation (1,712 participants from three trials):
| Low COE More data are needed. |
| HS vs. NS/placebo | |||
| Shein et al. (45) |
| Children on mechanical ventilation (18 participants):
| Very low COR. More data are needed. |
| Ezzeldin et al. (46) |
| Preterm infants on mechanical ventilation (100 participants):
| Very low COE. More data are needed. |
| rhDNase vs. placebo | |||
| Riethmueller et al. (47) |
| Infants on mechanical ventilation (100 participants):
| Very low COE More data are needed on children. |
| Youness et al. (48) |
| Adults on mechanical ventilation (33 participants in a three-arm trial):
| Very low COE More data are needed on children. |
| Zitter et al. (49) |
| Adults on mechanical ventilation (30 participants):
| Very low COE More data are needed on children. |
| NAC vs. NS | |||
| Masoompour et al. (50) |
| Adults on mechanical ventilation (40 participants):
| Very low COE. More data are needed on the pediatric population. |
Clinical studies of inhaled mucoactive drugs in children on mechanical ventilation.
COE, certainty of evidence; GRADE, grading of recommendations assessment, development and evaluation; HS, hypertonic saline; NAC, N-acetylcysteine; NS, normal saline; RCT, randomized controlled trial; rhDNase, recombinant human deoxyribonuclease I; VAP, ventilator-associated pneumonia.
3.6.1. Expert opinions/consensus recommendations
Inhaled HS (3%) has been shown to reduce the incidence density of VAP in intubated and mechanically ventilated premature infants. However, further research is needed in children (COR: III, disagreement, very low CoE).
Dornase alfa has been shown to reduce the length of stay and duration of ventilation in intubated and mechanically ventilated infants. However, further research is needed in children (COR: III, disagreement, very low CoE). It is also not available in India.
In adults, NAC has not been shown to be more effective than NS (COR: III, disagreement, very low CoE). Further data are needed on the pediatric population.
3.7. Tracheomalacia and tracheobronchomalacia
Tracheomalacia and tracheobronchomalacia have been increasingly recognized in children in recent years. Depending on the site and severity of the lesion, clinical presentation includes early onset stridor or fixed wheeze, recurrent infections, and cough (51). Isotonic saline or HS can aid in mucus clearance (52). Boogaard et al. found that in children with airway Tracheobronchomalacia and lower respiratory tract infections (Table 7A), the use of inhaled rhDNase did not enhance recovery from respiratory symptoms markedly cough, dyspnea, and difficulty in sputum expectoration (56).
Table 7
| Author and year | Study design | Key findings | Quality/CoE (per GRADE criteria) |
|---|---|---|---|
| 14 Tracheobronchomalacia (rhDNase vs. placebo) | |||
| Goyal et al. (53) | Systematic review | Children with airway tracheobronchomalacia and respiratory infection (40 from one trial):
| Very low COE More data are needed. |
| 15 EA with TEF (10% nebulized NAC vs. NS) | |||
| Singh et al. (54) | Non-RCT (Intervention study) | Children (30 participants):
| Very low COE More data are needed. |
| Pandey et al. (55) | Observational study | Children (7 participants):
| |
Clinical studies of inhaled mucoactive drugs in children with tracheobronchomalacia and EA with TEF.
COE, certainty of evidence; EA with TEF, esophageal atresia with tracheoesophageal fistula; GRADE, grading of recommendations assessment, development and evaluation; NAC, N-acetylcysteine; NS, normal saline; RCT, randomized controlled trial; rhDNase, recombinant human deoxyribonuclease I.
3.7.1. Expert opinion
There is limited evidence regarding the role of inhaled mucoactive drugs in patients with tracheomalacia and tracheobronchomalacia. Further research evaluating the efficacy and safety of inhaled mucoactive drugs in tracheomalacia and tracheobronchomalacia is needed in pediatric patients. (COR: III, disagreement, very low CoE).
3.8. Esophageal atresia with tracheoesophageal fistula
Congenital esophageal atresia (EA with tracheoesophageal fistula (TEF is a rare condition that occurs in 1 per 3,000 live births. Recurrent pneumonia, wheezing, and persistent cough are noted in these children (57). Inhaled NAC (Table 7B) has shown promising results in liquefying the airway secretions in EA with TEF and patients were discharged earlier than when treated with NS (54).
3.8.1. Expert opinions/consensus recommendations
There is limited evidence regarding the role of inhaled NAC in patients with EA with TEF. More prospective RCTs are required to make strong recommendations. (COR: III, disagreement, very low CoE).
3.9. Acute bronchiolitis
Acute bronchiolitis is a common cause of hospitalization and morbidity in infancy (58). The mainstay of therapy for acute bronchiolitis includes airway support, gentle nasal suctioning, fluid administration, and adequate nutrition (58, 59). Evidence (Table 8) suggests that inhaled HS shortened the length of hospital stay and improved the clinical severity score (in the first 3 days) in children with acute bronchiolitis (58, 63–65). Furthermore, treatment with inhaled HS may also substantially reduce the risk of hospitalization among outpatients and emergency department patients (58). Only one study assessed the effectiveness of inhaled NAC solution in children with acute bronchiolitis. In children with acute viral bronchiolitis, inhaled NAC in NS displayed an improvement in clinical severity score and resulted in early discharge from the hospital in children relative to salbutamol (62).
Table 8
| Author and year | Study design and study groups | Key findings | Quality/certainty of evidence (per GRADE criteria) |
|---|---|---|---|
| HS vs. NS/standard care | |||
| Zhang et al. (60) | Systematic review | Infants (5,205 from 34 trials):
| Low COE. More data are needed. |
| Nebulized rhDNase alone or in combination vs. placebo | |||
| Enriquez et al. (61) | Systematic review | Infants (333 from three trials):
| Very low COE. More data are needed. |
| NAC | |||
| Naz et al. (62) |
|
| Very low COE. More data are needed. |
Clinical studies of inhaled mucoactive drugs in children with acute bronchiolitis.
AE, adverse event; COE, certainty of evidence; ED, emergency department; GRADE, grading of recommendations assessment, development and evaluation; HS, hypertonic saline; NS, normal saline; RCT, randomized controlled trial; NAC, N-acetylcysteine; rhDNase, recombinant human deoxyribonuclease I.
3.9.1. Expert opinions/consensus recommendations
Inhaled HS therapy offers benefits in terms of reduced rate of hospitalization and readmission rates in infants and children with acute bronchiolitis. The experts suggested that inhaled salbutamol followed by HS (3%; every 6–8 h until discharge) may be considered in children with acute bronchiolitis (COR: II, conditional agreement, low CoE). The experts suggested that in certain phenotypes of bronchiolitis (history of atopy or wheezing), salbutamol may be considered.
Inhaled NAC is not studied well in acute bronchiolitis and is not commonly used in children with acute bronchiolitis. Multicenter RCTs are required to evaluate the efficacy and safety of inhaled NAC in children with acute bronchiolitis (very low CoE).
3.10. Sputum induction
Suri R et al. assessed the effectiveness (Table 9) of sputum induction (SI) with 7% inhaled HS on airway inflammation in children with CF (67). Sputum induction was found to be safe with no evidence of a proinflammatory effect. Furthermore, SI helped in the identification of organisms in culture-negative symptomatic children, circumventing the need for bronchoscopy (67). Ferreira et al. found that SI capacity was significantly increased in children with CF after 7% HS inhalation (68). Pathogen yield from SI was shown to be superior to cough swabs, and the technique can be used as a substitute for bronchoalveolar lavage in children with CF (69). Ultrasonic nebulizers are more successful in inducing sputum relative to jet nebulizers, and pretreatment with salbutamol can inhibit bronchoconstriction induced by HS inhalation (70). The usefulness of SI has also been studied in adult patients with pulmonary tuberculosis with 7% HS for improving bacteriological yield (71). The use of induced sputum samples was more sensitive than gastric washing specimens for the diagnosis of tuberculosis in patients who could not expectorate spontaneously (72).
Table 9
| Author and year | Study design and study groups | Key findings | Quality/certainty of evidence (per GRADE criteria) |
|---|---|---|---|
| HS for sputum induction in asthma | |||
| Gibson et al. (66) | Review Children >6 years with asthma (over 500 children from various studies):
|
| Very low COE More data are needed. |
| HS for sputum induction in CF | |||
| Suri et al. (67) |
| Children (48 from 1 study):
| Very low COE. More data are needed. |
| Ferreira et al. (68) |
| Children (64 from 1 study): Inhalation of 7% HS increased the sputum production and detection of pathogens. | |
| Ronchetti et al. (69) | Intervention study (internally controlled)
|
| |
Clinical studies of inhaled mucoactive drugs in SI.
CF, cystic fibrosis; GRADE, grading of recommendations assessment, development and evaluation; HS, hypertonic saline; SI, sputum induction.
3.10.1. Expert opinion/consensus recommendations
Nebulization with HS (7%) may be considered to facilitate sputum expectoration even in patients who usually do not expectorate (COR: II; conditional agreement, very low CoE). This method has been applied in patients with CF to enhance mucus clearance, for the identification of infectious agents, and for cytological examination in inflammatory airway disorders. It may avoid invasive interventions, such as bronchoscopy, to obtain better samples for pathogen detection (69).
A comparison of the efficacy and safety data of various strengths of HS for SI is required.
4. Discussion
Currently, there are no country-specific guidelines/recommendations for the treatment of pediatric respiratory diseases with inhaled mucoactive drugs from an Indian perspective. Studies have shown that Indian children differ in the etiology and clinical presentation of certain pediatric respiratory conditions (e.g., CF, non-CF bronchiectasis) compared to Western populations (73–75). Furthermore, due to a lack of well-designed RCTs in this field of study in India, medical practitioners rely on data from the Western world. To the best of our knowledge, this is the first practical consensus document to assist pediatricians in clinical decision-making when selecting an appropriate mucoactive medication for the management of certain respiratory illnesses based on the most recent available information. Experts recommended inhaled mucoactive drugs (HS, mannitol, and dornase alfa) in children with CF. Inhaled HS was conditionally recommended for CF, acute bronchiolitis, and PCD. Experts agreed that inhaled HS before chest physiotherapy may be helpful in children with non-CF bronchiectasis, although more research into the pediatric population is required. The current state of evidence is inadequate to support the use of mucoactive drugs in asthma, wheezing, tracheomalacia tracheobronchomalacia, and EA with TEF. Currently, dornase alfa and mannitol dry powder are not available for use in India. Dornase alfa therapy is expensive, but the drug can be imported and is certainly useful in patients who can afford it. An alternative lower-cost therapy is inhaled HS, which has shown benefits in CF, non-CF bronchiectasis, PCD, and acute bronchiolitis. Currently, 3% and 7% HS concentrations of HS are accessible in India.
4.1. Strengths
The panelists were chosen from across India based on their level of clinical expertise, academic distinctions, and involvement in relevant clinical research. The expert committee was formed without any bias in terms of selection.
4.2. Limitation
The patient's voice was not included in the consensus process.
5. Conclusion
In this article, we have summarized clinical consensus statements/recommendations on the role of inhaled mucoactive drugs in pediatric respiratory disease conditions from an Indian perspective. Children with CF would benefit from the initiation of HS inhalation (as an adjunct to ACT) from the time of diagnosis. Clinical evidence supports the benefits of inhalation of rhDNase and mannitol dry powder in patients with CF; however, these drugs are currently not available in India. Experts suggested that inhaled salbutamol followed by HS in non-CF bronchiectasis and acute bronchiolitis may be beneficial. Inhaled salbutamol followed by inhaled HS can increase mucus clearance in children with PCD with underlying bronchiectasis and persistent weight cough similar to other non-CF bronchiectasis. Dornase alfa has been shown to reduce the length of stay and duration of ventilation in intubated and mechanically ventilated infants; however, more data are needed in this regard. The current state of evidence is inadequate to support the use of mucoactive drugs in asthma, wheezing, tracheomalacia, tracheobronchomalacia, and EA with TEF. Further, prospective RCTs are required to make a strong recommendation. Lastly, population-based studies are required to validate the effectiveness of inhaled mucoactive drugs in Indian children with specific respiratory conditions where mucus hypersecretion is a clinical challenge.
Statements
Author contributions
MS: Conceptualization, Data curation, Writing – review & editing, Visualization. SV: Data curation, Visualization, Writing – review & editing. IK: Data curation, Visualization, Writing – review & editing. RD: Conceptualization, Data curation, Visualization, Writing – review & editing. JG: Data curation, Visualization, Writing – review & editing. MB: Data curation, Visualization, Writing – review & editing. RD: Data curation, Visualization, Writing – review & editing. PK: Data curation, Visualization, Writing – review & editing. JG: Data curation, Visualization, Writing – review & editing. IK: Data curation, Visualization, Writing – review & editing.
Funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
Acknowledgments
The authors acknowledge the role of ICMR Advanced Centre for Research in Evidence-based Child Health, PGIMER, Chandigarh. We would like to thank BioQuest Solutions for their editorial support. BioQuest Solutions received the unrestricted educational grant and logistical support from Cipla Ltd. for the consensus meeting.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped.2023.1322360/full#supplementary-material
References
1.
LinssenRSNMaJBemRARubinBK. Rational use of mucoactive medications to treat pediatric airway disease. Paediatr Respir Rev. (2020) 36:8–14. 10.1016/j.prrv.2020.06.007
2.
ShenYHuangSKangJLinJLaiKSunYet alManagement of airway mucus hypersecretion in chronic airway inflammatory disease: Chinese expert consensus (English edition). Int J Chron Obstruct Pulmon Dis. (2018) 13:399–407. 10.2147/COPD.S144312
3.
KnuutiJWijnsWSarasteACapodannoDBarbatoEFunck-BrentanoCet alESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. (2019) 41(3):407–77. Published correction appears in Eur Heart J. 2020 November 21;41(44):4242. 10.1093/eurheartj/ehz425
4.
SchünemannHBroekJGuyattGOxmanAD, Grade Working Group. GRADE handbook for grading quality of evidence and strength of recommendations. Available at:https://gdt.gradepro.org/app/handbook/handbook.html(Cited Jul 17 2023).
5.
AtkinsDBestDBrissPAEcclesMFalck-YtterYFlottorpSet alGrading quality of evidence and strength of recommendations. Br Med J. (2004) 328(7454):1490. 10.1136/bmj.328.7454.1490
6.
ChenQShenYZhengJ. A review of cystic fibrosis: basic and clinical aspects. Anim Models Exp Med. (2021) 4(3):220–32. 10.1002/ame2.12180
7.
WarkPMcDonaldVMSmithS. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev. (2023) 6(6):CD001506. 10.1002/14651858.CD001506.pub5
8.
RatjenFDavisSDStanojevicSKronmalRAHinckley StukovskyKDJorgensenNet alInhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. (2019) 7(9):802–9. 10.1016/S2213-2600(19)30187-0
9.
TiddensHAWMChenYAndrinopoulouERDavisSDRosenfeldMRatjenFet alThe effect of inhaled hypertonic saline on lung structure in children aged 3-6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial. Lancet Respir Med. (2022) 10(7):669–78. 10.1016/S2213-2600(21)00546-4
10.
ElkinsMDenticeR. Timing of hypertonic saline inhalation for cystic fibrosis. Cochrane Database Syst Rev. (2020) 2(2):CD008816. 10.1002/14651858.CD008816.pub4
11.
NevittSJThorntonJMurrayCSDwyerT. Inhaled mannitol for cystic fibrosis. Cochrane Database Syst Rev. (2020) 5(5):CD008649. 10.1002/14651858.CD008649.pub4
12.
SadrSKianiMRezaeiMKhanbabaeeGTabatabaeeSAHosseiniA. The efficacy of nebulized soluble mannitol and comparison with 5% hypertonic saline on pulmonary function of children with cystic fibrosis. J Compr Pediatr. (2019) 10(3):e85616. 10.5812/compreped.85616
13.
YangCMontgomeryM. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. (2021) 3(3):CD001127. 10.1002/14651858.CD001127.pub5
14.
DuijvestijnYCBrandPL. Systematic review of N-acetylcysteine in cystic fibrosis. Acta Paediatr. (1999) 88(1):38–41. 10.1111/j.1651-2227.1999.tb01265.x
15.
DonaldsonSHDanielle SamulskiTLaFaveCZemanKWuJTrimbleAet alA four-week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes. J Cyst Fibros. (2020) 19(6):942–8. 10.1016/j.jcf.2020.07.009
16.
StahlMWielpützMORicklefsIDopferCBarthSSchlegtendalAet alPreventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study. Am J Respir Crit Care Med. (2019) 199(10):1238–48. 10.1164/rccm.201807-1203OC
17.
ElkinsMRRobinsonMRoseBRHarbourCMoriartyCPMarksGBet alA controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. (2006) 354(3):229–40. 10.1056/NEJMoa043900
18.
De BoeckKHaarmanEHullJLandsLCMoellerAMunckAet alInhaled dry powder mannitol in children with cystic fibrosis: a randomised efficacy and safety trial. J Cyst Fibros. (2017) 16(3):380–7. 10.1016/j.jcf.2017.02.003
19.
AitkenMLBellonGDe BoeckKFlumePAFoxHGGellerDEet alLong-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med. (2012) 185(6):645–52. 10.1164/rccm.201109-1666OC
20.
FuchsHJBorowitzDSChristiansenDHMorrisEMNashMLRamseyBWet alEffect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The pulmozyme study group. N Engl J Med. (1994) 331(10):637–42. 10.1056/NEJM199409083311003
21.
QuanJMTiddensHASyJPMcKenzieSGMontgomeryMDRobinsonPJet alA two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr. (2001) 139(6):813–20. 10.1067/mpd.2001.118570
22.
SerisierDJShuteJKHockeyPMHigginsBConwayJCarrollMP. Inhaled heparin in cystic fibrosis. Eur Respir J. (2006) 27(2):354–8. 10.1183/09031936.06.00069005
23.
Máiz CarroLMartínez-GarcíaMA. Nebulized hypertonic saline in noncystic fibrosis bronchiectasis: a comprehensive review. Ther Adv Respir Dis. (2019) 13(13):1753466619866102. 10.1177/1753466619866102
24.
WelshEJEvansDJFowlerSJSpencerS. Interventions for bronchiectasis: an overview of cochrane systematic reviews. Cochrane Database Syst Rev. (2015) 2015(7):CD010337. 10.1002/14651858.CD010337.pub2
25.
TarrantBJLe MaitreCRomeroLStewardRButtonBMThompsonBRet alMucoactive agents for chronic, non-cystic fibrosis lung disease: a systematic review and meta-analysis. Respirology. (2017) 22(6):1084–92. 10.1111/resp.13047
26.
British Thoracic Society bronchiectasis guideline group-guideline for non-CF bronchiectasis in adults. (2019). Available at:https://www.brit-thoracic.org.uk/document-library/guidelines/bronchiectasis/bts-guideline-for-non-cf-bronchiectasis/
27.
AnuradhaKWDAGunathilakaPKGWickramasingheVP. Effectiveness of hypertonic saline nebulization in airway clearance in children with non-cystic fibrosis bronchiectasis: a randomized control trial. Pediatr Pulmonol. (2021) 56(2):509–15. 10.1002/ppul.25206
28.
KellettFRedfernJNivenRM. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir Med. (2005) 99(1):27–31. 10.1016/j.rmed.2004.05.006
29.
KellettFRobertNM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med. (2011) 105(12):1831–5. 10.1016/j.rmed.2011.07.019
30.
NicolsonCHStirlingRGBorgBMButtonBMWilsonJWHollandAE. The long-term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med. (2012) 106(5):661–7. 10.1016/j.rmed.2011.12.021
31.
BiltonDDaviskasEAndersonSDKolbeJKingGStirlingRGet alPhase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest. (2013) 144(1):215–25. 10.1378/chest.12-1763
32.
BiltonDTinoGBarkerAFChambersDCDe SoyzaADupontLJet alInhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax. (2014) 69(12):1073–9. 10.1136/thoraxjnl-2014-205587
33.
WillsPJWodehouseTCorkeryKMallonKWilsonRColePJ. Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability. Am J Respir Crit Care Med. (1996) 154(2 Pt 1):413–7. 10.1164/ajrccm.154.2.8756815
34.
O’DonnellAEBarkerAFIlowiteJSFickRB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. RhDNase study group. Chest. (1998) 113(5):1329–34. 10.1378/chest.113.5.1329
35.
AterDShaiHBarBEFiremanNTasherDDalalIet alHypertonic saline and acute wheezing in preschool children. Pediatrics. (2012) 129(6):e1397–403. 10.1542/peds.2011-3376
36.
KanjanapradapTDeerojanawongJSritippayawanSPrapphalN. Does nebulized hypertonic saline shorten hospitalization in young children with acute viral wheezing?Pediatr Pulmonol. (2018) 53(2):138–44. 10.1002/ppul.23924
37.
TeperAKofmanCAlchundia MoreiraJKöhlerTGarcía BournissenF. Bronchodilator response to albuterol nebulized with hypertonic saline in asthmatic children. Pediatr Pulmonol. (2021) 56(12):3714–9. 10.1002/ppul.25653
38.
BarbatoAFrischerTKuehniCESnijdersDAzevedoIBaktaiGet alPrimary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children. Eur Respir J. (2009) 34(6):1264–76. 10.1183/09031936.00176608
39.
KumarAWalkerWT. Management of a child with primary ciliary dyskinesia. Oxf Med Case Rep. (2020) 2020(2):omz135. 10.1093/omcr/omz135
40.
El-AbiadNMCliftonSNasrSZ. Long-term use of nebulized human recombinant DNase1 in two siblings with primary ciliary dyskinesia. Respir Med. (2007) 101(10):2224–6. 10.1016/j.rmed.2007.05.014
41.
PaffTDanielsJMWeersinkEJLutterRVonk NoordegraafAHaarmanEG. A randomised controlled trial on the effect of inhaled hypertonic saline on quality of life in primary ciliary dyskinesia. Eur Respir J. (2017) 49(2):1601770. 10.1183/13993003.01770-2016
42.
KaspyKAlarieNVallee-SmedjaSAdamJShapiroDF. Initiation of nebulized hypertonic saline in infants with primary ciliary dyskinesia. Am J Respir Crit Care Med. (2020) et al;201:A7768. 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A7768.
43.
StafangerGGarneSHowitzPMorkasselEKochC. The clinical effect and the effect on the ciliary motility of oral N-acetylcysteine in patients with cystic fibrosis and primary ciliary dyskinesia. Eur Respir J. (1988) 1(2):161–7. 10.1183/09031936.93.01020161
44.
AnandRMcAuleyDFBlackwoodBYapCONeillBConnollyBet alMucoactive agents for acute respiratory failure in the critically ill: a systematic review and meta-analysis. Thorax. (2020) 75(8):623–31. 10.1136/thoraxjnl-2019-214355
45.
SheinSLGallagherJTDeakinsKMWeinertDM. Prophylactic use of nebulized hypertonic saline in mechanically ventilated children: a randomized blinded pilot study. Respir Care. (2016) 61(5):586–92. 10.4187/respcare.04418
46.
EzzeldinZMansiYGaberMZakariaRFawzyRMohamedMA. Nebulized hypertonic saline to prevent ventilator associated pneumonia in premature infants, a randomized trial. J Matern Fetal Neonatal Med. (2018) 31(22):2947–52. 10.1080/14767058.2017.1359826
47.
RiethmuellerJBorth-BruhnsTKumpfMVontheinRWiskirchenJSternMet alRecombinant human deoxyribonuclease shortens ventilation time in young, mechanically ventilated children. Pediatr Pulmonol. (2006) 41(1):61–6. Published correction appears in Pediatr Pulmonol. 2006;41(4):388.10.1002/ppul.20298
48.
YounessHAMathewsKElyaMKKinasewitzGTKeddissiJI. Dornase alpha compared to hypertonic saline for lung atelectasis in critically ill patients. J Aerosol Med Pulm Drug Deliv. (2012) 25(6):342–8. 10.1089/jamp.2011.0954
49.
ZitterJNMaldjianPBrimacombeMFennellyKP. Inhaled dornase alfa (Pulmozyme) as a noninvasive treatment of atelectasis in mechanically ventilated patients. J Crit Care. (2013) 28(2):218.e1–e7. 10.1016/j.jcrc.2012.09.015
50.
MasoompourSMAnushiravaniATafaroj NorouzA. Evaluation of the effect of nebulized N-acetylcysteine on respiratory secretions in mechanically ventilated patients: randomized clinical trial. Iran J Med Sci. (2015) 40(4):309–15.
51.
WallisCAlexopoulouEAntón-PachecoJLBhattJMBushAChangABet alERS Statement on tracheomalacia and bronchomalacia in children. Eur Respir J. (2019) 54(3):1900382. 10.1183/13993003.00382-2019
52.
KamranAJenningsRW. Tracheomalacia and tracheobronchomalacia in pediatrics: an overview of evaluation, medical management, and surgical treatment. Front Pediatr. (2019) 7:512. 10.3389/fped.2019.00512
53.
GoyalVMastersIBChangAB. Interventions for primary (intrinsic) tracheomalacia in children. Cochrane Database Syst Rev. (2012) 10:CD005304. 10.1002/14651858.CD005304.pub3
54.
SinghGPandeyAShandilyaGGuptaARawatJDWakhluAet alEvaluation of nebulized N-acetyl cysteine in outcome of esophageal atresia with tracheoesophegeal fistula. J Pediatr Surg. (2020) 55(12):2635–9. 10.1016/j.jpedsurg.2020.04.013
55.
PandeyAGangopadhyayANSharmaSPKumarV. Esophageal atresia with tracheo-esophageal fistula: role of nebulized N-acetylcysteine in the outcome. J Indian Assoc Pediatr Surg. (2009) 14(4):232. 10.4103/0971-9261.59612
56.
BoogaardRde JongsteJCVaessen-VerberneAAHopWCMerkusPJ. Recombinant human DNase in children with airway malacia and lower respiratory tract infection. Pediatr Pulmonol. (2009) 44(10):962–9. 10.1002/ppul.21073
57.
PorcaroFValfréLAufieroLRDall’OglioLDe AngelisPVillaniAet alRespiratory problems in children with esophageal atresia and tracheoesophageal fistula. Ital J Pediatr. (2017) 43(1):77. 10.1186/s13052-017-0396-2
58.
ZhangLMendoza-SassiRAWainwrightCAregbesolaAKlassenTP. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. (2017) 12:CD006458. 10.1002/14651858.CD006458.pub4
59.
JoshiKPariharASSinghJ. Effect of nasal suction on reliving feeding difficulty in children affected with bronchiolitis. Int J Contemp Pediatr. (2020) 7(1):168–72. 10.18203/2349-3291.ijcp20195748
60.
ZhangLMendoza-SassiRAWainwrightCEKlassenTP. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. (2023) 4(4):CD006458. 10.1002/14651858.CD006458.pub5
61.
EnriquezAChuIWMellisCLinWY. Nebulised deoxyribonuclease for viral bronchiolitis in children younger than 24 months. Cochrane Database Syst Rev. (2012) 11(11):CD008395. 10.1002/14651858.CD008395.pub2
62.
NazFRazaABIjazIKaziMY. Effectiveness of nebulized N-acetylcysteine solution in children with acute bronchiolitis. J Coll Physicians Surg Pak. (2014) 24(6):408–11.
63.
ZhangLGuntherCBFrancoOSKlassenTP. Impact of hypertonic saline on hospitalization rate in infants with acute bronchiolitis: a meta-analysis. Pediatr Pulmonol. (2018) 53(8):1089–95. 10.1002/ppul.24066
64.
IslamMSMollahMAHKhanamRChowdhuryASRahmanMMAl BaquiSAAet alComparative efficacy of nebulized 7% hypertonic saline versus 0.9% normal saline with salbutamol in children with acute bronchiolitis. Bangladesh J Child Health. (2019) 43(2):80–4. 10.3329/bjch.v43i2.42550
65.
YuJFZhangYLiuZBWangJBaiLP. 3% Nebulized hypertonic saline versus normal saline for infants with acute bronchiolitis: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltim). (2022) 101(43):e31270. 10.1097/MD.0000000000031270
66.
GibsonPGGrootendorDCHenryRLPinIRytilaPHWarkPet alSputum induction in children. Eur Respir J Suppl. (2002) 37:44s–6s. 10.1183/09031936.02.00004402
67.
SuriRMarshallLJWallisCMetcalfeCShuteJKBushA. Safety and use of sputum induction in children with cystic fibrosis. Pediatr Pulmonol. (2003) 35(4):309–13. 10.1002/ppul.10226
68.
FerreiraACMMarsonFALCohenMABertuzzoCSLevyCERibeiroAFet alHypertonic saline as a useful tool for sputum induction and pathogen detection in cystic fibrosis. Lung. (2017) 195(4):431–9. 10.1007/s00408-017-0008-3
69.
RonchettiKTameJDPaiseyCThiaLPDoullIHoweRet alThe CF-sputum induction trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial. Lancet Respir Med. (2018) 6(6):461–71. 10.1016/S2213-2600(18)30171-1
70.
PopovTAPizzichiniMMPizzichiniEKolendowiczRPunthakeeZDolovichJet alSome technical factors influencing the induction of sputum for cell analysis. Eur Respir J. (1995) 8(4):559–65. 10.1183/09031936.95.08040559
71.
SeongGMLeeJLeeJHKimJHKimM. Usefulness of sputum induction with hypertonic saline in a real clinical practice for bacteriological yields of active pulmonary tuberculosis. Tuberc Respir Dis (Seoul). (2014) 76(4):163–8. 10.4046/trd.2014.76.4.163
72.
BrownMVariaHBassettPDavidsonRNWallRPasvolG. Prospective study of sputum induction, gastric washing, and bronchoalveolar lavage for the diagnosis of pulmonary tuberculosis in patients who are unable to expectorate. Clin Infect Dis. (2007) 44(11):1415–20. 10.1086/516782
73.
PrasadRSharmaHKaurG. Molecular basis of cystic fibrosis disease: an Indian perspective. Indian J Clin Biochem. (2010) 25(4):335–41. 10.1007/s12291-010-0091-1
74.
KumarALodhaRKumarPKabraSK. Non-cystic fibrosis bronchiectasis in children: clinical profile, etiology and outcome. Indian Pediatr. (2015) 52(1):35–7. 10.1007/s13312-015-0563-8
75.
ChandrasekaranRMac AogáinMChalmersJDElbornSJChotirmallSH. Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis. BMC Pulm Med. (2018) 18(1):83. 10.1186/s12890-018-0638-0
Summary
Keywords
mucoactive, inhaled, pediatric, respiratory disorders, consensus, India
Citation
Singh M, Varkki S, Kinimi I, Das RR, Goyal JP, Bhat M, Dayal R, Kalyan P, Gairolla J and Khosla I (2023) Expert group recommendation on inhaled mucoactive drugs in pediatric respiratory diseases: an Indian perspective. Front. Pediatr. 11:1322360. doi: 10.3389/fped.2023.1322360
Received
16 October 2023
Accepted
20 November 2023
Published
04 December 2023
Volume
11 - 2023
Edited by
Bülent Taner Karadağ, Marmara University, Türkiye
Reviewed by
Predrag B. Minić, University of Belgrade, Serbia Patrick Stafler, Schneider Children’s Medical Center, Israel
Updates
Copyright
© 2023 Singh, Varkki, Kinimi, Das, Goyal, Bhat, Dayal, Kalyan, Gairolla and Khosla.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Meenu Singh meenusingh4@gmail.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.